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Abstract: G protein-activated inwardly rectifying K
+ (GIRK) channels have been known to play a key role in the reward-
ing and analgesic effects of opioids. To identify potent agonists and antagonists to GIRK channels, we examined various 
compounds for their ability to activate or inhibit GIRK channels. A total of 503 possible compounds with low molecular 
weight were selected from a list of fluoxetine derivatives at Pfizer Japan Inc. We screened these compounds by a Xenopus 
oocyte expression system. GIRK1/2 and GIRK1/4 heteromeric channels were expressed on Xenopus laevis oocytes at 
Stage V or VI. A mouse IRK2 channel, which is another member of inwardly rectifying potassium channels with similar-
ity to GIRK channels, was expressed on the oocytes to examine the selectivity of the identified compounds to GIRK 
channels. For electrophysiological analyses, a two-electrode voltage clamp method was used. Among the 503 compounds 
tested, one compound and three compounds were identified as the most effective agonist and antagonists, respectively.  
All of these compounds induced only negligible current responses in the oocytes expressing the IRK2 channel, suggesting 
that these compounds were selective to GIRK channels. These effective and GIRK-selective compounds may be useful 
possible therapeutics for drug dependence and pain. 
Keywords: G protein-activated inwardly rectifying K
+ (GIRK, Kir3) channels, Kir channel, agonist, antagonist, Pfizer   
compounds, Xenopus oocyte. 
INTRODUCTION 
  G protein-activated inwardly rectifying K
+ (GIRK) chan-
nels, also named as Kir3 channels, are members of the in-
wardly rectifying potassium channel family. GIRK channels 
are activated by several Gi/o protein-coupled receptors, such 
as opioid receptors, which causes hyperpolarization of the 
neurons involved and thus leads to inhibitory regulation. 
GIRK channels are expressed in many tissues with different 
subunit compositions [1-3]. In the heart, the GIRK4 subunit 
is abundantly expressed as a homomultimer or heteromul-
timer with GIRK1 and is involved in heart rate regulation [4, 
5]. In the central nervous system, GIRK channels are mainly 
expressed as a GIRK1/2 heteromultimer in most regions and 
as a GIRK2 homomultimer in the substantia nigra and ven-
tral tegmental area. GIRK channels play a key role in analge-
sia [6], as demonstrated in studies using GIRK channel 
subunit knockout mice [7-11]. Further, mice lacking the 
GIRK2 or GIRK3 subunit show decreased cocaine self-
administration, suggesting decreased reinforcing effects of 
cocaine in these mice [12] and hence the involvement of 
GIRK channels in its rewarding effects. 
  Therefore, GIRK channel inhibitors may be possible 
candidates as therapeutic drugs to treat substance depend-
ence. Drugs that selectively open GIRK channels may be   
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expected to exhibit analgesic effects without impacting 
opioidergic intracellular signaling pathways and Gi/o proteins 
and thus have fewer side effects. It has been known that 
various compounds inhibit GIRK channels [13-17], but only 
a few have thus far been shown to activate the GIRK channel 
[18-20]. To identify more potent GIRK channel agonists and 
antagonists, we examined the ability of various compounds 
to activate or inhibit GIRK channels. 
METHODS 
Compounds 
  To search for selective GIRK channel agonists and an-
tagonists, a total of 503 possible compounds with low mo-
lecular weight were selected from a list of fluoxetine deriva-
tives at Pfizer Japan Inc. The specific names and detailed 
properties of each compound are not available to the public. 
For convenience, the compounds were numbered from PF 1 
to PF 503. All drugs were dissolved in dimethyl sulfoxide 
(DMSO). 
Electrophysiological Analysis 
  To screen the PF compounds, a Xenopus oocyte expres-
sion system was utilized based on a previous report [21]. In 
this system, murine GIRK1 (Kir3.1), GIRK2 (Kir3.2), and 
GIRK4 (Kir3.4) subunits were expressed as heteromeric 
channels of GIRK1/2 and GIRK1/4 in Xenopus laevis oo-
cytes at Stage V or VI by coinjection of the cRNAs of mouse 
GIRK1 and GIRK2 subunits, and GIRK1 and GIRK4 
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which is a member of another inwardly rectifying potassium 
channel family with similarity to the GIRK channel family, 
was expressed in the oocytes to examine the selectivity of 
the identified compounds to GIRK channels. For electro-
physiological analyses, a two-electrode voltage clamp 
(GeneClamp500, Axon Instruments) method was used with 
the membrane potential kept at -70 mV. A high potassium 
solution (96 mM KCl, 2 mM NaCl, 1 mM MgCl2, 1.5mM 
CaCl2, 5 mM HEPES) served as perfusion solution. Ethanol 
(100 mM) and BaCl2 (2 mM) were used as positive controls 
for agonist and antagonist, respectively, and DMSO was 
used as a negative control. Oocytes without cRNA injection 
served as controls. 
Assay Procedure 
  The procedure of the assay consisted of three steps. In the 
first step, among the total of 503 PF compounds, every four 
compounds were mixed together and dissolved in the high 
potassium solution to yield a solution containing each com-
pound at 10 μM. Then the total of 126 solutions of pooled PF 
compounds were applied to the oocytes expressing the 
GIRK1/2 channel (n = 2), GIRK1/4 channel (n = 2), and 
oocyte controls (n = 2) without GIRK channel expression. 
After the first screening step, several pools of compounds 
were selected based on the following criteria: (i) stronger 
agonistic or antagonistic effect on GIRK channels, (ii) simi-
lar responses between the two oocytes tested, and (iii) sub-
stantial difference in the effect of activation or inhibition 
between GIRK1/2 and GIRK1/4 channels. 
  In the second step, PF compounds in the selected pools 
(10 μM) were separately applied to the oocytes expressing 
the GIRK1/2 channel (n = 2), GIRK1/4 channel (n = 2), and 
oocyte controls (n = 2) without GIRK channel expression. 
Several compounds were selected based on the same criteria 
as those in the first step, in which their magnitude of inhibi-
tion/activation and the selectivity for the GIRK1/2 or 
GIRK1/4 channel were considered. 
  In the third step, each selected PF compound was applied 
to the oocytes expressing the GIRK1/2 channel (n = 5) and 
GIRK1/4 channel (n = 5) at various concentrations to exam-
ine concentration-response relationships. Selectivity of the 
compounds for GIRK channels was tested by applying the 
compounds to the oocytes expressing IRK2 (n = 2) and oo-
cyte controls (n = 2) without GIRK channel expression. Data 
were fitted to a standard regression equation by using Kalei-
daGraph 3.5J (HULINKS, Inc.) for analysis of concentra-
tion-response relationships. 
Statistical Analyses 
  The current responses to PF compounds were normalized 
by those to ethanol or BaCl2, which was applied to each oo-
cyte like PF compounds. For statistical analyses, two-way 
analysis of variance (ANOVA) or Student’s t-test was per-
formed with the significance level set at P < 0.05. SPSS 
v.12.0J for Windows (LEAD Technologies, Inc.) was used 
for analyses. 
RESULTS 
  In the first screening step, some pools of PF compounds 
showed agonistic effects on GIRK channels while most oth-
ers showed antagonistic effects on GIRK1/2 and GIRK1/4 
channels with various efficacies. All of the pools of PF com-
pounds induced negligible responses in the oocytes without 
cRNA injection (data not shown), suggesting the current 
responses by PF compounds were caused by exogenously 
expressed GIRK channels. Based on the criteria described 
above, PF 9 – PF 12, PF 401 – PF 404, and PF 409 – PF 412 
pools were selected as candidate agonists with relatively low 
percentage inhibition of GIRK currents compared to BaCl2 
responses, while PF 37 – PF 40, PF 157 – PF 160, PF 185 – 
PF 188, PF 233 – PF 236, and PF 245 – PF 248 pools were 
selected as candidate antagonists with relatively high per-
centage inhibition of GIRK currents (Fig. 1). In addition, the 
PF 417 – PF 420 pool was selected as candidate agonist or 
antagonist because it induced moderate inhibition of GIRK1/2 
channels and almost no effect on GIRK1/4 channels (Fig. 1). 
  In the second screening step, the PF compounds in the 
nine pools selected above were separately applied to the oo-
 
 
 
 
 
 
 
 
Fig. (1). Current Responses Induced by the Selected PF Compound Pools in the First Screening Step. Normalized current responses to 
the pools of PF compounds by the response to BaCl2. PF 9 – PF 12, PF 401 – PF 404, and PF 409 – PF 412 pools were selected as candidate 
agonists, and PF 37 – PF 40, PF 157 – PF 160, PF 185 – PF 188, PF 233 – PF 236, and PF 245 – PF 248 pools were selected as candidate 
antagonists. The PF 417 – PF 420 pool was selected as a candidate agonist or antagonist in the first screening step. Identification of Selective Agonists and Antagonists to G Protein-Activated  Current Neuropharmacology, 2011, Vol. 9, No. 1    115 
cytes. While most of these individual PF compounds showed 
antagonistic effects or almost no effect on GIRK channels, 
only PF 419 showed an apparent agonistic effect on both 
GIRK1/2 and GIRK1/4 cannels (Fig. 2a, b). Therefore, PF 
419 was selected as a candidate agonist. In addition, PF 40, 
PF 236, and PF 246, which induced comparatively higher 
percentage inhibition of GIRK currents, were selected as 
candidate antagonists (Fig. 2b). 
  In the third screening step, the four PF compounds se-
lected above (PF 419, PF 40, PF 236, PF 246) were applied 
to the oocytes expressing the GIRK1/2 channel (n = 5) and 
GIRK1/4 channel (n = 5) at various concentrations. Consid-
ering the results in our preliminary experiments testing the 
effect of each compound at 0.1, 1, and 10 μM (data not 
shown), the concentrations of each compound to examine the 
concentration-response relationships were set at 1, 3, 10, 30, 
and 100 μM. Fig. (3) represents the concentration-response 
relationships for each PF compound. PF 419 activated GIRK 
currents dose-dependently, whereas PF 40, PF 236, and PF 
246 inhibited them dose-dependently. Two-way ANOVA 
revealed that there were significant main effects of the con-
centrations of PF compounds on the current responses to PF 
419 (F4,40 = 8.606, P < 0.001), PF 40 (F4,40 = 75.475, P < 
0.001), PF 236 (F4,40 = 80.160, P < 0.001), and PF 246 (F4,40 
= 227.702, P < 0.001). There were significant main effects of 
the GIRK subunit compositions on the current responses in 
PF 419 (F1,40 = 6.078, P = 0.018), PF 40 (F1,40 = 19.865, P < 
0.001), and PF 236 (F1,40 = 50.590, P < 0.001). Significant 
interactions were observed between the concentrations and 
GIRK subunit compositions in PF 40 (F4,40 = 3.252, P = 
0.021) and PF 236 (F4,40 = 4.371, P = 0.005). Post hoc analy-
sis revealed a significant difference between the GIRK1/2 
and GIRK1/4 channels at 100 μM (P = 0.004) in PF 419,  
at 30 μM (P = 0.004) and 100 μM (P < 0.001) in PF 40,  
and at 10 μM (P = 0.001), 30 μM (P < 0.001), and 100 μM 
(P < 0.001) in PF 236 (Fig. 3). Inhibition concentration 
(IC50) values were calculated for PF 40, PF 236, and PF 246 
(Table 1). In addition, we examined the selectivity of these 
compounds for GIRK channels by applying them to oocytes 
expressing the IRK2 channel (n = 2). All four compounds 
showed almost no or negligible effects on IRK2 channels 
(data not shown), suggesting that these compounds were 
selective for GIRK channels. 
DISCUSSION 
  In the first step of the screening process, most pools of 
PF compounds showed apparent antagonistic effects and a 
few showed agonistic effects on GIRK channels, possibly 
because the PF compounds used in the present assay were 
selected from the fluoxetine derivatives that are known to 
inhibit GIRK channels [22]. However, several pools of PF 
compounds exhibited almost no effects on GIRK channels. It 
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Fig. (2). Candidate Agonist and Antagonists Identified in the Second Screening Step. PF 419 was selected as a candidate agonist, and PF 
40, PF 236, and PF 246 were selected as candidate antagonists in the second screening step. a. Traces of typical current responses to PF 419 
(30 μM) and BaCl2 (2 mM) in the oocyte expressing the GIRK1/4 channel. The striped and filled bars represent the duration of the applica-
tion of PF 419 and BaCl2, respectively. b. The normalized current responses to the selected PF compounds by the response to BaCl2. 116    Current Neuropharmacology, 2011, Vol. 9, No. 1  Nishizawa et al. 
might be possible that agonists and antagonists were com-
bined in a pool which effectively negated their possible ac-
tions on GIRK channels. Therefore, if different combinations 
of PF compounds had been pooled, different agonists   
and antagonists might have been identified after the overall 
screening procedure. 
  As shown in Table 1, the IC50 values for PF 40, PF 236, 
and PF 246 calculated in the third screening step ranged 
from 5.98 to 31.2. These were comparable to, or lower than, 
those of various antipsychotic drugs [14-16], indicating they 
could be more potent antagonists than therapeutic drugs cur-
rently available. In addition, the agonistic effect of PF 419 at 
10 μM or higher was several times that of ethanol (100 mM), 
a well-known GIRK agonist [18, 19], indicating that PF 419 
is a very potent GIRK agonist. In a comparison between 
GIRK1/2 and GIRK1/4, significant differences were   
observed in PF 419, PF 40, and PF 236 (Fig. 3), suggesting 
that PF 40 and PF 236 are antagonists relatively selective to 
GIRK1/2 and PF 419 is an agonist relatively selective to 
GIRK1/4. 
Table 1.  IC50 Values of the Antagonists Selected in the   
Overall Screening 
 PF40  PF236  PF246 
GIRK1/2 6.06  5.98  24 
(95%CI) (4.03-8.68)  (3.09-10.3)  (13.4-55.6) 
GIRK1/4 16.6  31.2  27.5 
(95%CI) (8.03-44.7)  (15.2-107)  (16.7-54.8 
CI: confidence intervals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Concentration-Response Relationships of the Identified Agonist and Antagonists to GIRK Channels. a. Current response was 
normalized by the response to ethanol (100 mM). b-d. Current responses were normalized by the response to BaCl2 (2 mM). *P < 0.005 
between GIRK1/2 and GIRK1/4. **P < 0.001 between GIRK1/2 and GIRK1/4. Identification of Selective Agonists and Antagonists to G Protein-Activated  Current Neuropharmacology, 2011, Vol. 9, No. 1    117 
  In conclusion, by screening a total of 503 PF compounds, 
one compound and three compounds were identified as the 
most effective agonist and antagonists, respectively. These 
compounds were all selective for GIRK channels. These 
effective and GIRK-selective compounds may be useful, 
therefore, as possible therapeutics for drug dependence and 
pain. 
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